Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospec
- PDF / 712,692 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 25 Downloads / 194 Views
IM - ORIGINAL
Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID‑19 mortality: a retrospective cohort study Ashkan Yahyavi1 · Nima Hemmati1 · Pegah Derakhshan1 · Behrooz Banivaheb1 · Arman Karimi Behnagh1 · Rozhin Tofighi1 · Alireza TehraniYazdi2 · Ali Kabir1 Received: 27 May 2020 / Accepted: 29 September 2020 © Società Italiana di Medicina Interna (SIMI) 2020
Abstract Targeting the renin-angiotensin system is proposed to affect mortality due to coronavirus disease 2019 (COVID-19). We aimed to compare the mortality rates in COVID-19 patients who received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) and those who did not. In this retrospective cohort study, mortality was considered as the main outcome measure. All underlying diseases were assessed by the chronic use of medications related to each condition. We defined two main groups based on the ACEIs/ARBs administration. A logistic regression model was designed to define independent predictors of mortality as well as a Cox regression analysis. In total, 2553 patients were included in this study. The mortality frequency was higher in patients with a history of underlying diseases (22.4% vs 12.7%, P value
Data Loading...
